On June, 13 The EPS for Myovant Sciences Ltd. (MYOV) Expected At $-0.77

May 17, 2018 - By Darrin Badillo

Myovant Sciences Ltd. (NYSE:MYOV)’s earnings report is anticipated by WallStreet on June, 13, according to Faxor. After $-0.70 EPS report last quarter, Wall Street now predicts 10.00 % negative EPS growth of Myovant Sciences Ltd.. MYOV is touching $21.7 during the last trading session, after decreased 2.34%.Currently Myovant Sciences Ltd. is uptrending after 79.46% change in last May 17, 2017. MYOV has also 48,877 shares volume. The stock outperformed the S&P 500 by 67.91%.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases.The firm is valued at $1.35 billion. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.Currently it has negative earnings. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction.

There’s a substantial Myovant Sciences Ltd. (NYSE:MYOV) news published by Prnewswire.com. It’s an item titled: “Myovant Sciences and PERIOD. Inc. Launch Partnership Focused on Empowering Women to Elevate the Conversation …” on April 20, 2018.

Myovant Sciences Ltd. (NYSE:MYOV) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: